Quest Diagnostics Inc (NYSE:DGX)
$ 206.84 -0.82 (-0.39%) Market Cap: 22.90 Bil Enterprise Value: 29.29 Bil PE Ratio: 22.86 PB Ratio: 3.12 GF Score: 80/100

Q1 2025 Quest Diagnostics Inc Earnings Call Transcript

Apr 22, 2025 / 12:30PM GMT
Release Date Price: $172.84 (+6.78%)

Key Points

Positve
  • Quest Diagnostics Inc (DGX) reported strong revenue growth of approximately 12% in the first quarter, with nearly 2.5% in organic growth.
  • The company reaffirmed its revenue and adjusted EPS guidance for the full year 2025, indicating confidence in its financial outlook.
  • Quest Diagnostics Inc (DGX) expanded its use of automation, robotics, and AI to improve quality, customer and employee experiences, and productivity.
  • The company was named as the first independent national lab to be selected to the Optum Health Preferred Lab Network, enhancing its reputation and partnerships.
  • Quest Diagnostics Inc (DGX) saw impressive uptake of its novel PFAS forever chemicals test, demonstrating successful innovation and market adoption.
Negative
  • Organic volume growth was down by 0.9%, impacted by weather and one less day in the quarter compared to the prior year.
  • Higher interest expenses impacted EPS in the first quarter, with reported EPS at $1.94 compared to $1.72 a year ago.
  • The company faces potential challenges from tariffs, although it believes the impact is manageable under current regulations.
  • There are ongoing labor strikes at LifeLabs in British Columbia, which could impact operations and financial performance.
  • Quest Diagnostics Inc (DGX) continues to face challenges in the health system pricing landscape, which remains the most difficult area to manage.
Operator

Welcome to the Quest Diagnostics first-quarter 2025 conference call. At the request of the company, this call is being recorded. The entire contents of the call, including the presentation and question-and-answer session that will follow, are the copyrighted property of Quest Diagnostics with all rights reserved.

Any redistribution, retransmission or rebroadcast of this call in any form without written consent of Quest Diagnostics is strictly prohibited. Now I'd like to introduce Shawn Bevec, Vice President and Investor Relations for Quest Diagnostics. Please go ahead.

Shawn Bevec
Quest Diagnostics Inc - Vice President - Investor Relations

Thank you, and good morning. I'm joined by Jim Davis, our Chairman, Chief Executive Officer and President; and Sam Samad, our Chief Financial Officer. During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release.

Any actual results may differ materially

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot